208 related articles for article (PubMed ID: 30336071)
21. A role for Follistatin-like protein 1 (FSTL1) in colorectal cancer.
Voutsadakis IA
Ann Transl Med; 2020 Mar; 8(5):155. PubMed ID: 32309304
[No Abstract] [Full Text] [Related]
22. Follistatin-like Protein 1 Inhibits Lung Cancer Metastasis by Preventing Proteolytic Activation of Osteopontin.
Chiou J; Chang YC; Tsai HF; Lin YF; Huang MS; Yang CJ; Hsiao M
Cancer Res; 2019 Dec; 79(24):6113-6125. PubMed ID: 31653686
[TBL] [Abstract][Full Text] [Related]
23. Fstl1/DIP2A/MGMT signaling pathway plays important roles in temozolomide resistance in glioblastoma.
Nie E; Miao F; Jin X; Wu W; Zhou X; Zeng A; Yu T; Zhi T; Shi Z; Wang Y; Zhang J; Liu N; You Y
Oncogene; 2019 Apr; 38(15):2706-2721. PubMed ID: 30542120
[TBL] [Abstract][Full Text] [Related]
24. miR-137 alleviates doxorubicin resistance in breast cancer through inhibition of epithelial-mesenchymal transition by targeting DUSP4.
Du F; Yu L; Wu Y; Wang S; Yao J; Zheng X; Xie S; Zhang S; Lu X; Liu Y; Chen W
Cell Death Dis; 2019 Dec; 10(12):922. PubMed ID: 31801953
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA-137 Inhibits Cancer Progression by Targeting Del-1 in Triple-Negative Breast Cancer Cells.
Lee SJ; Jeong JH; Kang SH; Kang J; Kim EA; Lee J; Jung JH; Park HY; Chae YS
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817673
[TBL] [Abstract][Full Text] [Related]
26. Expression of miR-335 in triple-negative breast cancer and its effect on chemosensitivity.
Hao J; Lai M; Liu C
J BUON; 2019; 24(4):1526-1531. PubMed ID: 31646803
[TBL] [Abstract][Full Text] [Related]
27. Follistatin‑like protein 1 knockdown elicits human gastric cancer cell apoptosis via a STAT6‑dependent pathway.
Peng X; Wang P; Li S; Jiang Y; Wu C
Oncol Rep; 2019 Dec; 42(6):2806-2813. PubMed ID: 31578589
[TBL] [Abstract][Full Text] [Related]
28. Non-coding RNAs as potential therapeutic targets in breast cancer.
Tomar D; Yadav AS; Kumar D; Bhadauriya G; Kundu GC
Biochim Biophys Acta Gene Regul Mech; 2020 Apr; 1863(4):194378. PubMed ID: 31048026
[TBL] [Abstract][Full Text] [Related]
29. Molecular functions of FSTL1 in the osteoarthritis.
Li W; Alahdal M; Deng Z; Liu J; Zhao Z; Cheng X; Chen X; Li J; Yin J; Li Y; Wang G; Wang D; Tang K; Zhang J
Int Immunopharmacol; 2020 Jun; 83():106465. PubMed ID: 32259701
[TBL] [Abstract][Full Text] [Related]
30. FSTL1 promotes nitric oxide-induced chondrocyte apoptosis via activating the SAPK/JNK/caspase3 signaling pathway.
Xu C; Jiang T; Ni S; Chen C; Li C; Zhuang C; Zhao G; Jiang S; Wang L; Zhu R; van Wijnen AJ; Wang Y
Gene; 2020 Mar; 732():144339. PubMed ID: 31927008
[TBL] [Abstract][Full Text] [Related]
31. Follistatin-like 1 as a Novel Adipomyokine Related to Insulin Resistance and Physical Activity.
Xu X; Zhang T; Mokou M; Li L; Li P; Song J; Liu H; Zhu Z; Liu D; Yang M; Yang G
J Clin Endocrinol Metab; 2020 Dec; 105(12):. PubMed ID: 32894773
[TBL] [Abstract][Full Text] [Related]
32. LncCCAT1 Promotes Breast Cancer Stem Cell Function through Activating WNT/β-catenin Signaling.
Tang T; Guo C; Xia T; Zhang R; Zen K; Pan Y; Jin L
Theranostics; 2019; 9(24):7384-7402. PubMed ID: 31695775
[No Abstract] [Full Text] [Related]
33. Sulforaphene inhibits the progression of osteosarcoma via regulating FSTL1/NF-κB pathway.
Zhang G; Jin C; Zhu Y; Fu F; Wang G; Li S
Life Sci; 2020 Dec; 263():118485. PubMed ID: 33017573
[TBL] [Abstract][Full Text] [Related]
34. Structural and functional study of FK domain of Fstl1.
Li X; Li L; Chang Y; Ning W; Liu X
Protein Sci; 2019 Oct; 28(10):1819-1829. PubMed ID: 31351024
[TBL] [Abstract][Full Text] [Related]
35. LncRNA BCRT1 promotes breast cancer progression by targeting miR-1303/PTBP3 axis.
Liang Y; Song X; Li Y; Chen B; Zhao W; Wang L; Zhang H; Liu Y; Han D; Zhang N; Ma T; Wang Y; Ye F; Luo D; Li X; Yang Q
Mol Cancer; 2020 May; 19(1):85. PubMed ID: 32384893
[TBL] [Abstract][Full Text] [Related]
36. LINC00160 mediated paclitaxel-And doxorubicin-resistance in breast cancer cells by regulating TFF3 via transcription factor C/EBPβ.
Wu H; Gu J; Zhou D; Cheng W; Wang Y; Wang Q; Wang X
J Cell Mol Med; 2020 Aug; 24(15):8589-8602. PubMed ID: 32652877
[TBL] [Abstract][Full Text] [Related]
37. CDK12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS1-ErbB-PI3K signaling.
Choi HJ; Jin S; Cho H; Won HY; An HW; Jeong GY; Park YU; Kim HY; Park MK; Son T; Min KW; Jang KS; Oh YH; Lee JY; Kong G
EMBO Rep; 2019 Oct; 20(10):e48058. PubMed ID: 31468695
[TBL] [Abstract][Full Text] [Related]
38. Follistatin-like 1 protects mesenchymal stem cells from hypoxic damage and enhances their therapeutic efficacy in a mouse myocardial infarction model.
Shen H; Cui G; Li Y; Ye W; Sun Y; Zhang Z; Li J; Xu G; Zeng X; Zhang Y; Zhang W; Huang Z; Chen W; Shen Z
Stem Cell Res Ther; 2019 Jan; 10(1):17. PubMed ID: 30635025
[TBL] [Abstract][Full Text] [Related]
39. HIF-2α promotes conversion to a stem cell phenotype and induces chemoresistance in breast cancer cells by activating Wnt and Notch pathways.
Yan Y; Liu F; Han L; Zhao L; Chen J; Olopade OI; He M; Wei M
J Exp Clin Cancer Res; 2018 Oct; 37(1):256. PubMed ID: 30340507
[TBL] [Abstract][Full Text] [Related]
40. Long non-coding RNA LUCAT1/miR-5582-3p/TCF7L2 axis regulates breast cancer stemness via Wnt/β-catenin pathway.
Zheng A; Song X; Zhang L; Zhao L; Mao X; Wei M; Jin F
J Exp Clin Cancer Res; 2019 Jul; 38(1):305. PubMed ID: 31300015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
